Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,918,995

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Merck (MRK) Q1 Earnings and Revenues Lag Estimates

Merck (MRK) delivered earnings and revenue surprises of -14.11% and -5.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Sweta Killa headshot

Healthcare ETFs on Radar As Q1 Earnings Unfold

Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate returns.

Why Merck (MRK) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More

Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.

Is a Beat Likely for AstraZeneca (AZN) in Q1 Earnings?

AstraZeneca's (AZN) first-quarter results are expected to reflect the impact of strong demand for new drugs as well as coronavirus-led disruption. Investors are likely to focus on COVID-19 vaccine related updates.

David Borun headshot

Stocks Have First Down Week in Five on Tax Hike Fears

Stocks fall after a proposed rise in capital gains taxes, but make up most of the lost ground with a Friday rally.

Merck (MRK) to Report Q1 Earnings: What's in the Cards?

Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.

Will Strong Veklury and HIV Sales Aid Gilead's (GILD) Q1 Earnings?

Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports first-quarter 2021 results.

Merck (MRK) Reports Next Week: Wall Street Expects Earnings Growth

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (BIIB) Q1 Earnings Top, Sales Down as Key Drugs Falter

Biogen (BIIB) beats first-quarter estimates for both earnings and sales and ups earnings guidance for 2021.

Merck (MRK) Gains As Market Dips: What You Should Know

Merck (MRK) closed the most recent trading day at $78.57, moving +1.17% from the previous trading session.

Seagen's (SGEN) Two sBLAs for Padcev Gets FDA Priority Review

The FDA accepts Seagen (SGEN) and Astellas' two sBLAs for Padcev under a priority review to treat patients with locally advanced or metastatic urothelial carcinoma. A verdict is pending on Aug 17, 2021.

J&J (JNJ) Q1 Earnings Top, COVID-19 Vaccine Brings $100M Sales

J&J (JNJ) beats first-quarter 2021 estimates for both earnings and sales. It boosts quarterly dividend by 5%.

Bristol Myers (BMY) Opdivo Gets FDA Nod for Gastric Cancer

Bristol Myers (BMY) obtains FDA approval for Opdivo in combination with chemotherapy for patients with gastric cancer, among others.

Merck (MRK) Stops MK-7110 Development, Focuses on Molnupiravir

Merck (MRK) will start evaluating oral molnupiravir in non-hospitalized COVID-19 patients in a late-stage study. It stops MK-7110 development due to requirement of additional studies.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's COVID-19 Vaccine Woes, MRK Ends COVID-19 Drug Development

FDA & CDC temporarily halt J&J's (JNJ) COVID-19 vaccine use. Merck (MRK) ends development of COVID-19 drug.

Will Solid Pharma Unit Performance Drive J&J (JNJ) Q1 Earnings?

In J&J's (JNJ) Pharma segment, its oncology drugs, Imbruvica and Darzalex as well as psoriasis treatment drug, Stelara, are likely to have driven sales growth.

Bristol Myers' (BMY) Opdivo Combo Gets EU Nod for First-Line RCC

The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Cabometyx for first-line treatment of advanced renal cell carcinoma.

Merck (MRK) Stock Moves -0.04%: What You Should Know

Merck (MRK) closed the most recent trading day at $76.40, moving -0.04% from the previous trading session.

The Zacks Analyst Blog Highlights: Home Depot, Toyota, International Business Machines, Merck and CVS Health

The Zacks Analyst Blog Highlights: Home Depot, Toyota, International Business Machines, Merck and CVS Health

Sheraz Mian headshot

Top Research Reports for Home Depot, Toyota & IBM

Today's Research Daily features new research reports on 16 major stocks, including The Home Depot (HD), Toyota Motor (TM), and International Business Machines (IBM).

Bristol Myers' (BMY) Opdivo Combo Encouraging in NSCLC study

Bristol Myers Squibb (BMY) announces positive results from a late-stage study evaluating Opdivo plus chemotherapy for resectable NSCLC.

Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Bristol Myers' (BMY) Opdivo Combo Positive in ESCC Study

Bristol Myers (BMY) announces encouraging data from the late-stage study evaluating Opdivo plus chemotherapy and Opdivo plus Yervoy in ESCC study.

Merck (MRK) Keytruda Meets Endpoint in Kidney Cancer Study

Merck (MRK) is developing a Keytruda monotherapy regimen for adjuvant treatment of renal cell carcinoma patients.